-+ 0.00%
-+ 0.00%
-+ 0.00%

Trinity Biotech Q1 FY26 net loss narrows to $4.4 million; revenue rises 43% to $10.8 million

PUBT·06/16/2026 13:10:54
Listen to the news
Trinity Biotech Q1 FY26 net loss narrows to $4.4 million; revenue rises 43% to $10.8 million
  • Trinity Biotech Q1 2026 revenue rose 43% to $10.8 million.
  • Gross margin climbed 10.2 percentage points to 35.4%.
  • Net loss narrowed to $4.4 million; adjusted EBITDA improved to negative $1.1 million.
  • Received purchase orders for over 2 million TrinScreen HIV tests, scheduled for Q3 2026 fulfillment.
  • CEO John Gillard cited recent Ebola and Hantavirus outbreaks as highlighting ongoing infectious-disease public health risks.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trinity Biotech plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606160910PRIMZONEFULLFEED9747759) on June 16, 2026, and is solely responsible for the information contained therein.